Spontaneous rescue from cystic fibrosis in a mouse model

BMC Genetics

Volumn 7, Issue , 2006, Pages

  Charizopoulou, Nikoletta ^a   Wilke, Martina ^b   Dorsch, Martina ^a   Bot, Alice ^b   Jorna, Huub ^b   Jansen, Silke ^a   Stanke, Frauke ^a   Hedrich, Hans J ^a   de Jonge, Hugo R ^b   Tümmler, Burkhard ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; FEMALE; INTESTINE EPITHELIUM; LUNG PARENCHYMA; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; NOSE MUCOSA; NUCLEOTIDE SEQUENCE; OUTBRED STRAIN; PATHOPHYSIOLOGY; PHENOTYPE; RNA SPLICING; STRAIN DIFFERENCE; WILD TYPE;

ANIMALS; CHLORIDES; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DISEASE MODELS, ANIMAL; ELECTRIC CONDUCTIVITY; FEMALE; GENOMICS; GENOTYPE; IMMUNOHISTOCHEMISTRY; INTESTINAL MUCOSA; MICE; MICE, INBRED CFTR; MICE, MUTANT STRAINS; MICROSATELLITE REPEATS; PHENOTYPE; RESPIRATORY MUCOSA; RNA SPLICING; RNA, MESSENGER;

ANIMALIA;

EID: 33646205698     PISSN: 14712156     EISSN: 14712156     Source Type: Journal    
DOI: 10.1186/1471-2156-7-18     Document Type: Article

References (60)

1. Riordan J, Rommens J, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou J, Drumm M, Iannuzzi M, Collins F, Tsui LC: Identification of the cystic fibrosis gene: cloning and characterisation of complementary DNA. Science 1989, 245:1066-1073.
2. Dorin JR, Dickinson P, Alton EWFW, Smith N, Geddes DM, Stevenson BJ, Kimber WL, Fleming S, Clarke AR, Hooper ML, Anderson L, Beddington RSP, Porteous DJ: Cystic fibrosis in the mouse by targeted insertional mutagenesis. Nature 1992, 359:211-215.
3. Dorin JR, Stevenson BJ, Fleming S, Alton EWFW, Dickinson P, Porteous DJ: Long term survival of the exon 10 insertional cystic fibrosis mutant mouse is a consequence of low level residual wild-type Cftr gene expression. Mamm Genome 1994, 5:465-472.
4. Chiba-Falek O, Parad RB, Kerem E, Kerem B. Variable levels of normal RNA in different fetal organs carrying a cystic fibrosis transmembrane conductance regulator splicing mutation. Am J Respir Crit Care Med 1999, 159:1998-2002.
5. Ramalho AS, Beck S, Meyer M, Penque D, Cutting GR, Amaral MD: Five percent of normal cystic fibrosis transmembrane conductance regulator mRNA ameliorates the severity of pulmonary disease in cystic fibrosis. Am J Respir Cell Mol Biol 2002, 27:619-627.
6. Pagani F, Stuani C, Tzetis M, Kanavakis E, Efthymiadou A, Doudounakis S, Casals T, Baralle FE: New type of disease causing mutations: the example of the composite exonic regulatory elements of splicing in CFTR exon 12. Hum Mol Genet 2003, 12:1111-1120.
7. Teng H, Jorissen M, Van Poppel H, Legius E, Cassiman J-J, Cuppens H: Increased proportion of exon 9 alternatively spliced CFTR transcripts in vas deferens compared with nasal epithelial cells. Hum Mol Genet 1997, 6:85-90.
8. Chiba-Falek O, Kerem E, Shoshani T, Aviram M, Augarten A, Bentur L, Tal A, Tullis E, Rahat A, Kerem B: The molecular basis of disease variability among cystic fibrosis patients carrying the 3849+10 kb C-T mutation. Genomics 1998, 53:276-283.
9. Nissim-Rafinia M, Aviram M, Randell SH, Shushi L, Ozeri E, Chiba-Falek O, Eidelman O, Pollard HB, Yankaskas JR, Kerem B: Restoration of the cystic fibrosis transmembrane conductance regulator function by splicing modulation. EMBO reports 2004, 5:1071-1077.
10. Davidson JD, Dorin JR, McLachlan G, Ranaldi V, Lamp D, Doherty C, Govan J, Porteous DJ: Lung disease in cystic fibrosis mouse exposed to bacterial pathogens. Nat Genet 1995, 9:351-357.
11. Smith SN, Steel DM, Middleton PG, Munkonge FM, Geddes DM, Caplen NJ, Porteous DJ, Dorin JR, Alton EWFW: Bioelectric characteristics of exon 10 insertional cystic fibrosis mouse: comparison with humans. Am J Physiol 1995, 268(Cell Physiol 37):C297-C307.
12. Rydziel S, Delany AM, Canalis E: AU-rich elements in the collagenase 3 mRNA mediated stabilisation of the transcript by cortisone in osteoblasts. J Biol Chem 2004, 279:5397-5404.
13. Pasmooij AM, van Zalen S, Nijenhuis AM, Kloosterhuis AJ, Zuiderveen J, Jonkman MF, Pas HH: A very mild form of non-Herlitz junctional epidermolysis bullosa: BP 180 rescue by outsplicing of mutated exon 30 coding for the COL 15 domain. Exp Dermatol 2004, 13:125-128.
14. McLean WH, Irvine AD, Hamill KJ, Whittock NV, Coleman-Campbell CM, Mellerio JE, Ashton GS, Dopping-Hepenstal PJ, Eady RA, Jamil T, Phillips RJ, Shabbir SG, Haroon TS, Khurshid K, Moore JE, Page B, Darling J, Atherton DJ, Van Steensel MA, Munro CS, Smith FJ, McGrath JA: An unusual N-terminal deletion of the laminin alpha3a isoform leads to the chronic granulation tissue disorder laryngo-onycho-cutaneous syndrome. Hum Mol Gen 2003, 12:2395-2409.
15. Ozisik G, Mantovani G, Achermann JC, Persani L. Spada A, Weiss J, Beck-Peccoz P, Jameson JL: An alternate translation initiation site circumvents an amino-terminal DAXI nonsense mutation leading to a mild form of X-linked adrenal hypoplasia congenita. J Clin Endocrinol Metab 2003, 88:417-423.
16. Hwang T-C, Wang F, Yang IC-H, Reenstra WW: Genistein potentiates wild-type and F508del-CFTR channel activity. Am J Physiol 1997, 273(Cell Physiol 42):C988-C998.
17. Illek B, Zhang L, Lewis NC, Moss RB, Dong J-Y, Fischer H: Defective function of the cystic fibrosis-causing missense mutation G551D is recovered by genistein. Am J Physiol 1999, 277(Cell Physiol 46):C833-C839.
18. Charizopoulou N, Stanke F, Dorsch M, Hedrich HJ, Tümmler B: High-throughput and cost effective genome wide microsatellite genotyping of two novel cystic fibrosis mutant mouse strains. J Gen Sci Techn 2004, 3:30-37.
19. Niksic M, Romano M, Buratti E, Pagani F, Baralle FE: Functional analysis of cis-acting elements regulating the alternative splicing of human CFTR exon 9. Hum Mol Genet 1999, 8:2339-2349.
20. Buratti E, Baralle FE: Characterisation and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9. J Biol Chem 2001, 276:36337-36343.
21. Nissim-Rafinia M, Chiba-Falek O, Sharon G, Boss A, Kerem B: Cellular and viral splicing factors can modify the splicing pattern of CFTR transcripts carrying splicing mutations. Hum Mol Genet 2000, 9:1771-1778.
22. Mouchel N, Henstra. SA, McCarthy VA, Williams SH, Phylactides M, Harris A: HNFIa is involved in tissue-specific regulation of CFTR gene expression. Biochem J 2004, 378:909-918.
23. Bach G, Moskowitz SM, Tieu PT, Matynia A, Neufeld EF: Molecular analysis of Hurler syndrome in Druze and Muslim Arab patients in Israel: multiple allelic mutations of the IDUA gene in a small geographic area. Am J Hum Genet 1993, 53:330-338.
24. Dietz HC, Valle D, Francomano CA, Kendzior RJ Jr, Pyeritz RE, Cutting GR: The skipping of constitutive exons in vivo induced by nonsense mutations. Science 1993, 259:680-682.
25. Gibson RA, Hajianpour A, Murer-Orlando M, Buchwald M, Mathew CG: A nonsense mutation and exon skipping in the Fanconi anaemia group C gene. Hum Mol Genet 1993, 2:797-799.
26. Hull J, Shackleton S, Harris A: The stop mutation R553X in the CFTR gene results in exon skipping. Genomics 1994, 19:362-364.
27. Orci L, Stamnes M, Ravazzola M, Amherdt M, Perrelet A, Sollner TH, Rothman JE: Bidirectional transport by distinct populations of COPI-coated vesicles. Cell 1997, 90:335-349.
28. Zhang H, Peters KW, Sun F, Marino CR, Langs J, Burgoyne RD, Frizzell RA: Cysteine string protein interacts with and modulates the maturation of the cystic fibrosis transmembrane conductance regulator. J Biol Chem 2002, 277:28948-28958.
29. Yun CH, Oh S, Zizak M, Steplock D, Tsao S, Tse CM, Weinman EJ, Donowitz M: cAMP-mediated inhibition of the epithelial brush border Na+/H+ exchanger, NHE3, requires an associated regulatory protein. Proc Natl Acad Sci USA 1997, 94:3010-3015.
30. Lamprecht G, Weinman EJ, Yun CH: The role of NHERF and E3KARP in the cAMP-mediated Inhibition of NHE3. J Biol Chem 1998, 273:29972-29978.
31. Wang S, Yu H. Derin RB, Guggino WB, Li M: CAP70, a positive regulator for the chloride channel activity of CFTR. Pediatr Pulmonol 1999:246.
32. Cheng J, Moyer BD, Milewski M, Hazama A, Mickle JE, Cutting GR, Stanton BA, Guggino WB: CFTR associates with the PDZ domain protein CAL at the trans-Golgi network. Pediatr Pulmonol 1999:168.
33. Low SH, Chapin SJ, Wimmer C, Whiteheart SW, Komuves LG, Mostov KE, Weimbs T: The SNARE machinery is involved in apical plasma membrane trafficking in MDCK cells. J Cell Biol 1998, 141:1503-1513.
34. Lambert G, Becker B, Schreiber R, Boucherot A, Reth M, Kunzelmann K: Control of cystic fibrosis transmembrane conductance regulator expression by BAP31. J Biol Chem 2001, 276:20340-20345.
35. Yoo JS, Moyer BD, Bannykh S, Yoo HM, Riordan JR, Balch WE: Nonconventional trafficking of the cystic fibrosis conductance regulator through the early secretory pathway. J Biol Chem 2002, 277:11401-11409.
36. Gentzsch M, Chang XB, Cui L, Wu Y, Ozols VV, Choudhury A, Pagano RE, Riordan JR: Endocytic trafficking routes of wild type and deltaF508 cystic fibrosis transmembraneconductance regulator. Mol Biol Cell 2004, 15:2684-2696.
37. Vankeerberghen A. Cuppens H, Cassiman JJ: The cystic fibrosis transmembrane conductance regulator: an intriguing protein with pleiotropic functions. J Cyst fibros 2002, 1:13-29.
38. Ko SBH, Zeng W, Dorwart MR, Luo X, Kim KH, Millen L, Goto H, Naruse S, Soyombo A, Thomas PJ, Muallem S: Gating of CFTR by the STAS domain of SLC26 transporters. Nat Cell Biol 2004, 6:343-350.
39. Zoo X, Hwang TC: ATP hydrolysis-coupled gating of CFTR chloride channels: structure and function. Biochemistry 2001, 40:5579-5586.
40. Highsmith WE, Burch LH, Zhou Z, Olsen JC, Boat TE, Spock A, Gorvoy JD, Quittel L, Friedman KJ, Silverman LM: A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations. N Engl J Med 1994, 331:974-980.
41. Highsmith WE, Burch LH, Zhou Z, Olsen JC, Strong TV, Smith T, Friedman KJ, Silverman LM, Boucher RC, Collins FS, Knowles MR: Identification of a splice site mutation (2789+5G-A) associated with small amounts of normal CFTR mRNA and mild cystic fibrosis. Hum Mutat 1997, 9:332-338.
42. Chu CS, Trapnell BC, Curristin S, Cutting GR, Crystal RG: Genetic basis of variable exon 9 skipping in cystic fibrosis transmembrane conductance regulator mRNA. Nat Genet 1993, 3:151-156.
43. s polymorphism as a disease mutation. J Clin Invest 1998, 101:487-496.
44. Groman JD, Hefferon TW, Casals T, Bassas L, Estivill X, Des Georges M, Guittard C, Koudova M, Fallin MD, Nemeth K., Fekete G, Kadasi L, Friedman K, Schwarz M, Bombieri C, Pignatti PF, Kanavakis E, Tzetis M, Schwartz M, Novelli G, D'Apice MR, Sobczynska-Tomaszewska A, Bal J, Stuhrmann M, Macek M Jr, Claustres M, Cutting GR: Variation in a repeat sequence determines whether common variant of the cystic fibrosis transmembrane conductance regulator gene is pathogenic or benign. Am J Hum Genet 2003, 74:176-179.
45. Rave-Harel N, Kerem E, Nissim M, Madjar I, Goshen R, Augarten A, Rahat A, Hurwitz A, Darvasi A, Kerem B: The molecular basis of partial penetrance of splicing mutations in cystic fibrosis. Am J Hum Genet 1997, 60:87-94.
46. Buratti E, Dörk T, Zuccato E, Pagani F, Romano M, Baralle FE: Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping. EMBO J 2001, 20:1774-1784.
47. Pagani F, Stuani C, Zuccato E, Kornblihtt AR, Baralle FE: Promoter architecture modulates CFTR exon 9 skipping. J Biol Chem 2003, 278:1511-1517.
48. Pagani F, Buratti E, Stuani C, Baralle FE: Missense, nonsense, and neutral mutations define juxtaposed regulatory elements of splicing in cystic fibrosis transmembrane regulator exon 9. J Biol Chem 2003, 278:26580-26588.
49. Cohen FE, Kelly JW: Therapeutic approaches to protein-misfolding diseases. Nature 2003, 426:905-909.
50. Wagner E, Lykke-Andersen J: mRNA surveillance: the perfect persist. J Cell Science 2002, 115:3033-3038.
51. Gross-Bellard M, Oudet P, Chambon P: Isolation of high molecular weight DNA from mammalian cells. Eur J Biochem 1973, 36:32-38.
52. Mouse Genome Informatics (MGI) [http://www.informatics.jax.org]
53. Mekus F, Dörk T, Deufel T, Tümmler B: Analysis of microsatellites by direct blotting electrophoresis and chemiluminescence detection. Electrophoresis 1995, 16:1886-1888.
54. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidine thiocyanate-phenol-chloroform extraction. Anal Biochem 1987, 162:156-159.
55. Hoof T, Riordan JR, Tümmler B: Quantitation of transcript by the kinetic polymerase chain reaction assay: a tool for monitoring P-glycoprotein gene expression. Anal Biochem 1991, 196:161-169.
56. Bremer S, Hoof T, Wilke M, Busche R, Scholte B, Riordan JR, Maass G, Tümmler B: Quantitative expression patterns of multidrug-resistance P-glycoprotein (MDRI) and differentially spliced cystic-fibrosis transmembrane-conductance regulator mRNA transcripts in human epithelia. Eur J Biochem 1992, 206:137-149.
57. van Dommelen FS, Hamer CM, de Jonge HR: Efficient entrapment of large and small compounds during vesiculation of intestinal microvilli. Biochem J 1986, 236:771-778.
58. French PJ, van Doornick JH, Peters RHPC, Verbeek E, Ameen NA, Marino CR, de Jonge HR, Bijman J, Scholte BJ: A F508del mutation in mouse cystic fibrosis transmembrane conductance regulator results in a temperature-sensitive processing defect in vivo. J Clin Invest 1996, 98:1304-1312.
59. Devys D, Lutz Y, Rouyer N, Bellocq JP, Mandel JL: The FMR-1 Protein is cytoplasmic, most abundant in neurons and appears normal in carriers of a fragile X permutation. Nat Genet 1993, 4:335-340.
60. 2+-mediated CI- secretion in nasal epithelia of CF mice. Am J Physiol 1994, 266(Cell Physioll 35):C1478-C1483.